Clinical trial · Observational
Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia
An Observational, Retrospective and Multicenter Study to Evaluate the Effectiveness and Safety of 1L (PEG)+ Ascorbic Acid Given for Bowel Preparation Prior to Colonoscopy in Iberia
NCT05174845CI-TRIAL-00058803completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A retrospective study to evaluate the effectiveness and safety of 1L polyethylene glycol (PEG)+ Ascorbic acid given for bowel preparation before colonoscopy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Colon Cleansing | — | UNRESOLVED | — |
| Colon Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1L PEG + ASCORBIC ACID | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Number of patients With Successful Bowel Cleansing (Overall Colon)
- timeFrame
- Up to 2 days (from day of first dosing to day of colonoscopy)
- description
- The proportion of patients with adequate total colon cleansing is defined as a Boston Bowel preparation scale (BBPS) score ≥ 2 in all segments (BBPS\> 6).
- measure
- Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens)
- timeFrame
- Up to 2 days (from day of first dosing to day of colonoscopy)
- description
- Proportion of patients with a high-quality cleaning in the right colon defined as a BBPS score = 3.
Secondary outcomes (13)
- measure
- Polyps Detection Rate in the total colon and in the right colon
- timeFrame
- Up to 2 days (from day of first dosing to day of colonoscopy)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male and female outpatients aged: ≥18 years undergoing a screening, surveillance, or diagnostic colonoscopy between June 1, 2019, to September 1, 2021 * Who have used NER1006 in the preparation of the colonoscopy either in split doses or same day. Exclusion Criteria: * History of colorectal cancer o colectomy before the first colonoscopy * Impossibility to obtain the required mandatory data
References
Publications (0)
Data not yet available
No reference posted for this study.